Clinical Trial Update: A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports that the study evaluating Tabelecleucel for Epstein-Barr virus–associated diseases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Cell Transplant
• Ebv-positive Lymphoproliferative Disease with Acquired Immunodeficiency
• Ebv-positive Lymphoproliferative Disease with Primary Immunodeficiency
• Ebv-positive Post-transplant Lymphoproliferative Disease
• Ebv-positive Post-transplant Lymphoproliferative Disease of the Central Nervous System
• Epstein-barr Virus Associated Diseases
• Lymphoproliferative Disorders
• Solid Organ Transplant Complications

Drugs mentioned

• Tabelecleucel (tabelecleucel)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD) | Phase 2 | Status: RECRUITING